GeneNews Limited: bringing the blood transcriptome to personalized medicine.

GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine. GeneNews has developed and patented the Sentinel Principle(®), an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome. Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of malignancy, including those for oncology, cardiovascular, metabolic and neurological related disorders. Currently available products and services from GeneNews are: ColonSentry™, the world's first blood-based molecular test for colorectal cancer, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts.